Book contents
- Stories of Stroke
- Stories of Stroke
- Copyright page
- Contents
- Contributors
- Why This Book Needed to Be Written
- Preface
- Part I Early Recognition
- Part II Basic Knowledge, Sixteenth to Early Twentieth Centuries
- Part III Modern Era, Mid-Twentieth Century to the Present
- Types of Stroke
- Chapter Fifteen Carotid Artery Disease
- Chapter Sixteen Lacunes
- Chapter Seventeen Vertebrobasilar Disease
- Chapter Eighteen Aneurysms and Subarachnoid Hemorrhage
- Chapter Nineteen Intracerebral Hemorrhage
- Chapter Twenty Vascular Malformations
- Chapter Twenty One Cerebral Venous Thrombosis
- Chapter Twenty Two Arterial Dissections, Fibromuscular Dysplasia, Moyamoya Disease, and Reversible Cerebral Vasoconstriction Syndrome
- Chapter Twenty Three Blood Disorders
- Chapter Twenty Four Stroke Genetics
- Chapter Twenty Five Eye Vascular Disease
- Chapter Twenty Six Spinal Cord Vascular Disease
- Some Key Physicians
- Imaging
- Care
- Treatment
- Part IV Stroke Literature, Organizations, and Patients
- Index
- References
Chapter Twenty Three - Blood Disorders
from Types of Stroke
Published online by Cambridge University Press: 13 December 2022
Book contents
- Stories of Stroke
- Stories of Stroke
- Copyright page
- Contents
- Contributors
- Why This Book Needed to Be Written
- Preface
- Part I Early Recognition
- Part II Basic Knowledge, Sixteenth to Early Twentieth Centuries
- Part III Modern Era, Mid-Twentieth Century to the Present
- Types of Stroke
- Chapter Fifteen Carotid Artery Disease
- Chapter Sixteen Lacunes
- Chapter Seventeen Vertebrobasilar Disease
- Chapter Eighteen Aneurysms and Subarachnoid Hemorrhage
- Chapter Nineteen Intracerebral Hemorrhage
- Chapter Twenty Vascular Malformations
- Chapter Twenty One Cerebral Venous Thrombosis
- Chapter Twenty Two Arterial Dissections, Fibromuscular Dysplasia, Moyamoya Disease, and Reversible Cerebral Vasoconstriction Syndrome
- Chapter Twenty Three Blood Disorders
- Chapter Twenty Four Stroke Genetics
- Chapter Twenty Five Eye Vascular Disease
- Chapter Twenty Six Spinal Cord Vascular Disease
- Some Key Physicians
- Imaging
- Care
- Treatment
- Part IV Stroke Literature, Organizations, and Patients
- Index
- References
Summary
Marcello Malpighi (1628–1694), an Italian physiologist and physician, is credited with introducing the microscope into medicine. He was probably the first to study blood clotting. He examined both thrombi in the heart and in vitro blood clots using a light microscope and found that their structures were similar. He described red blood cells for the first time and noted the appearance of a meshwork of fibrous texture that later was labeled “fibrin” [1].
- Type
- Chapter
- Information
- Stories of StrokeKey Individuals and the Evolution of Ideas, pp. 200 - 210Publisher: Cambridge University PressPrint publication year: 2022
References
Notes and References
Müller, Johannes. Handbuch der Physiologie des Menschen. 4 editions. Coblenz: J. Hölscher, 1835–1840.Google Scholar
Safavi-Abbasi, S, Reis, C, Talley, MC, et al. Rudolf Ludwig Karl Virchow: Pathologist, physician, anthropologist, and politician. Implications of his work for the understanding of cerebrovascular pathology and stroke. Neurosurg. Focus 2006 Jun 15;20(6):E1.CrossRefGoogle Scholar
Dickson, BC. Venous thrombosis: On the history of Virchow’s Triad. University of Toronto Medical Journal 2004;166–171.Google Scholar
Virchow, Rudolf. Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre. Berlin: A. Hirschwald, 1858.Google Scholar
Virchow, Rudolf. Über die akute Entzündung der Arterien. Arch. Path. Anat. Physiol. 1847;1:272–378.CrossRefGoogle Scholar
Schiller, F. Concepts of stroke before and after Virchow. Med. Hist. 1970;14:115–131.CrossRefGoogle ScholarPubMed
Schmidt, A. Neue Untersuchungen ueber die asserstoffesgerinnung. Pflügers Archiv für die gesamte Physiologie 1872;6:413–538.CrossRefGoogle Scholar
Ribatti, D, Crivellato, E. Giulio Bizzozero and the discovery of platelets. Leukemia Research 2007;31(10):1339–1341.CrossRefGoogle ScholarPubMed
Boulton, F. A hundred years of cascading – Started by Paul Morawitz (1879–1936), a pioneer of haemostasis and of transfusion. Transfus. Med. 2006;16(1):1–10.CrossRefGoogle ScholarPubMed
Morawitz, P. Die Chemie der Blutgerinnung. Ergebnisse der Physiologie 1905;4:307–423.CrossRefGoogle Scholar
Dirckx, JH. Armand, J. Quick: Pioneer and prophet of coagulation research. Ann. Intern. Med. 1980;92(4):553–558.CrossRefGoogle ScholarPubMed
Ebel, EM. The Quick Tests: The Life and Work of Dr. Armand J. Quick. Blacksburg, VA: Pocahontas Press, 1995.Google Scholar
Quick, AJ. The development and use of the prothrombin tests. Circulation 1959;19(1):92–96.Google Scholar
Rosenberg, RD, Aird, WC. Vascular-bed-specific hemostasis and hypercoagulable states. N. Engl. J. Med. 1999;340(20):1555–1564.Google Scholar
Bauer, KA. Inherited and acquired hypercoagulable states. In Loscalzo, J, Schafer, AK (eds.), Thrombosis and Hemorrhage, 2nd ed. Baltimore, MD: Williams & Wilkins, 1998, pp. 863–900.Google Scholar
Dahlbäck, B, Carlsson, M, Svensson, PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA 1993;90:1004–1008.Google Scholar
Bertina, RM, Koeleman, BP, Koster, T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369(6475):64–67.CrossRefGoogle ScholarPubMed
Voorberg, J, Roelse, J, Koopman, R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994;343(8912):1535–1536.Google ScholarGoogle ScholarGoogle Scholar
Koster, MDT, Vandenbrouke, JPV, Rosendaal, FR, de Ronde, H, Bertina, RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503–1506.CrossRefGoogle ScholarPubMed
Rosendaal, FR, Koster, T, Vandenbroucke, JP, Reitsma, PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85(6):1504–1508.CrossRefGoogle ScholarPubMed
Poort, SR, Rosendaal, FR, Reitsma, PH, Bertina, RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88(10):3698–3703.Google Scholar
Leroyer, C, Mercier, B, Oger, E, et al. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb. Haemost. 1998;80(1):49–51.Google ScholarPubMed
McCully, KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 1969;56(1):111–128.Google ScholarPubMed
Carson, NAJ, Neill, DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch. Dis. Child 1962;37:505–513.CrossRefGoogle Scholar
Clarke, R, Daly, L, Robinson, K, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N. Engl. J. Med. 1991;324(17):1149–1155.Google ScholarGoogle Scholar
Mudd, SH, Skovby, F, Levy, HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am. J. Hum. Genet. 1985;37:1–31.Google ScholarPubMed
Kang, SS, Zhou, J, Wong, PW, Kowalisyn, J, Strokosch, G. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase. Am. J. Hum. Genet. 1988;43(4):414–421.Google ScholarPubMed
Selhub, J, Jacques, PF, Wilson, PW, Rush, D, Rosenberg, IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270(22):2693–2698.Google Scholar
Svenungsson, E, Antovic, A. The antiphospholipid syndrome – often overlooked cause of vascular occlusions? J. Intern. Med. 2020;7(4):349–372.Google Scholar
Mueller, JF, Ratnoff, O, Heinle, RW. Observations on the characteristics of an unusual circulating anticoagulant. J. Lab. Clin. Med. 1951;8(2):254–261.Google Scholar
Conley, CL, Hartmann, RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J. Lab. Clin. Invest. 1952;31:621–622.Google ScholarGoogle Scholar
Hughes, GR, Asherson, RA, Khamashta, MA. Antiphospholipid syndrome: Linking many specialties. Ann. Rheum. Dis. 1989;48:355–356.CrossRefGoogle ScholarPubMed
de Groot, PG, Meijers, JCM. β(2)-Glycoprotein I: Evolution, structure and function. J. Thromb. Haemost. 2011;9(7):1275–1284.Google Scholar
Wilson, WA, Gharavi, AE, Koike, T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum. 1999;42:1309–1311.Google ScholarGoogle Scholar
Levine, JS, Ware Branch, D, Rauch, J. The antiphospholipid syndrome. N. Engl. J. Med. 2002;346(10):752–763.CrossRefGoogle ScholarPubMed
Ziporen, L, Goldberg, I, Arad, M, et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: Immunopathologic findings in deformed heart valves. Lupus 1996;5(3):196–205.CrossRefGoogle ScholarPubMed
Provenzale, JM, Barboriak, DP, Allen, NB, Ortel, TL. Antiphospholipid antibodies: Findings at arteriography. AJNR Am. J. Neuroradiol. 1998;19:611–616.Google Scholar
Levine, SR, Brey, RL, Tilley, BC, Thompson, JL, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004;291:576–584.Google ScholarPubMed
Urbanus, RT, Siegerink, B, Roest, M, Rosendaal, FR, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischemic stroke in young women in the RATIO study: A case control study. Lancet Neurol. 2009;8:998–1005.Google Scholar
Asherton, RA. The catastrophic antiphospholipid syndrome. J. Rheumatol. 1992;19:508–512.Google Scholar
Bucciarelli, S, Espinosa, G, Cervera, R. The CAPS Registry: Morbidity and mortality of the catastrophic antiphospholipid syndrome. Lupus 2009;18(10):905–912.CrossRefGoogle ScholarPubMed